Jungbunzlauer's Tricalcium Citrate Sets New Standards in Pharma
Innovative Advancements by Jungbunzlauer in Tablet Manufacturing
- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications -
Jungbunzlauer, a global leader in sustainable ingredient solutions, in collaboration with experts from the Department of Pharmaceutical Technology and Biopharmaceutics at the University of Bonn, has announced ground-breaking results that showcase the exceptional performance of their tricalcium citrate (TCC TB) in direct compression for pharmaceutical tablet manufacturing.
Significant Findings in Direct Compression Studies
Research conducted with Professor Karl Wagner emphasizes the role of TCC TB in refining direct compression processes, crucial for pharmaceutical applications. This formulation meets the rigorous demands of both pharmaceutical and nutraceutical sectors, establishing new benchmarks for quality and efficiency. Markus Gerhart, Senior Director at Jungbunzlauer, stated that this collaboration illustrates their dedication to using science to drive innovation and excellence.
Performance Characteristics of TCC TB
Direct compression is gaining popularity in the industry due to its efficiency and suitability for delicate ingredients, yet it necessitates excipients that exhibit excellent flowability and compactibility. The results of the studies have confirmed that TCC TB excels in these aspects, showcasing remarkable flowability and ensuring robust tablet strength even under low compression force. Furthermore, it demonstrates rapid disintegration properties, making it suitable for challenging formulations such as minitablets and moisture-sensitive active pharmaceutical ingredients (APIs).
Sustainability and Quality Standards
TCC TB is produced through the complete neutralization of citric acid with a high purity calcium source, making it a vegan option while being free from allergens and GMOs. It meets stringent standards set forth by USP, FCC, and EU regulations, ensuring its suitability for global markets.
Event Participation and Knowledge Sharing
Jungbunzlauer is set to showcase these findings at the CPHI Global event in Messe Frankfurt, where attendees can interact with their team and discuss how TCC TB could support their formulation challenges. This participative approach reflects Jungbunzlauer's commitment to collaboration and innovation within the sector.
About Jungbunzlauer
Jungbunzlauer stands as a pioneer in producing sustainable ingredients sourced from nature. The company caters to diverse industries, including food and beverage, health, and personal care, with a mission to offer naturally superior ingredients that uplift everyday life. With a fortified portfolio that includes texturants, sweeteners, and tailored solutions, Jungbunzlauer continues to evolve alongside customer needs.
Headquartered in Basel, Switzerland, and supported by state-of-the-art facilities throughout Europe and North America, Jungbunzlauer proudly serves clients in over 130 countries. Founded more than 150 years ago, the company has grown into a powerhouse with a revenue of CHF 1.3 billion, driven by the dedication of nearly 1,400 employees working towards a healthier future.
Frequently Asked Questions
What is the main advantage of TCC TB in tablet manufacturing?
The TCC TB offers exceptional flowability and tablet strength, making it suitable for direct compression in pharmaceutical applications.
How does Jungbunzlauer ensure the quality of its products?
Jungbunzlauer's TCC TB meets stringent quality standards set by USP, FCC, and EU regulations.
What makes TCC TB a sustainable option?
TCC TB is produced from high purity materials and is vegan, allergen-free, and GMO-free, aligning with sustainable practices.
How can I learn more about Jungbunzlauer's offerings?
You can explore Jungbunzlauer's diverse range of ingredients and solutions on their official website.
Where can I see Jungbunzlauer present their findings?
Jungbunzlauer will showcase their innovative solutions at CPHI Global in Messe Frankfurt.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.